HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA

Clinical trials for HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1 Terminated 1

New drug under Real-World watch for tough stomach cancer

Disease control Recruiting now

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …

Matched conditions: HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control

Last updated Jun 27, 2026 12:30 UTC

HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA

Get alerted when new HER2-POSITIVE ADVANCED GASTRIC ADENOCARCINOMA trials appear

New drug under Real-World watch for tough stomach cancer